

Supporting Information for

One Stone Two Birds: β -Fluoropyrrolyl-Cysteine S_NAr Chemistry Enabling Functional Porphyrin Bioconjugation

Guo-Qing Jin¹, Jing-Xiang Wang¹, Jianhua Lu¹, Hang Zhang¹, Yuhang Yao¹, Yingying Ning¹, Hua Lu¹, Song Gao^{1,2,3}, and Jun-Long Zhang^{1,2*}

¹Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, P. R. China

²Chemistry and Chemical Engineering Guangdong Laboratory, Shantou 515031, P. R. China

³ Spin-X Institute, School of Chemistry and Chemical Engineering, State Key Laboratory of Luminescent Materials and Devices, Guangdong-Hong Kong-Macao Joint Laboratory of Optoelectronic and Magnetic Functional Materials, South China University of Technology, Guangzhou 510641, China

Contents

I. Materials and Methods	3
Materials	3
Methods	4
General procedures	4
Synthesis of substrates	6
Reaction rate	17
P ₁₂ reacted with GSH	18
P ₁₃ reacted with GSH	18
Click chemistry	18
Protein bioconjugation	18
Synthesis of P ₁₃ -EGFP-PDS and IAA-EGFP-PDS	19
Metabolic labeling of Sialoglycoproteins	19
Measurement of ¹ O ₂ generation efficiency	19
Cytotoxicity evaluation <i>in vitro</i>	20
Cellular internalization measured by confocal laser scanning microscopy (CLSM)	20
Enzymatic assay of caspase-3 in solutions	20
Fluorescence imaging of caspase-3 in live HeLa cells	20
Fluorescence imaging of A549/MCF7	21
<i>In vivo</i> photodynamic therapy assay	21
Structures of β -peptidyl porphyrins	22
II. Supporting Tables and Figures	33
III. Reference	154

I. Materials and Methods

Materials.

All reagents were purchased from commercial suppliers and used as received unless otherwise indicated below.

Chemical reagents used in this work are listed in the format of (trade name; agency, article number): 1-dimethylamino-2-propyne (HEOWNS, 7223-38-3), dibenzocyclooctyne-PEG₄-N-hydroxysuccinimidyl ester (DBCO-PEG₄-NHS; Sigma-Aldrich, 764019), disulfo-Cy5-DBCO (Confluore, BCD-34), sulfo-DBCO-amine (Click Chemistry Tools, 1227), tris[(1-hydroxypropyl-1H-1,2,3-triazol-4-yl)methyl]amine (THPTA; Sigma-Aldrich, 762342), 2-iminothiolane (J & K Scientific, 455901), Biotin-PEG₄-alkyne (Confluore, BCP-14), Ac₄ManNAz (Confluore, BSMB-3), lipoic acid (LA; Macklin, A835604), Staurosporine (STS, Amethyst, 970545), 5-[(S)-(+)-2-(methoxymethyl)pyrrolidino]sulfonylisatin (MPS, EFEBIO, E005702). H₂O was obtained from Milli-Q integral, HPLC grade methanol was purchased from Fisher. All mobile phase were filtered with 0.22 μm filter membrane in advance.

3,4-Difluoropyrrole was synthesized according to literature methods.¹

Peptides were purchased from ChinaPeptides. Streptavidin (Sav) was purchased from Thermo Fisher Scientific. Bovine serum albumin (BSA) was purchased from Sigma-Aldrich. Recombinant human Caspase-3 and recombinant human Caspase-7 were both purchased from Sino Biological Inc. (Beijing, China). The EGFP was expressed according to literature method.^{2,3} The sequence is shown as following:

MENLYFQCGKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTCLKFICTTGKLPVPWPTLVTTL
TYGVQCFSRYPDHMKQHDFKSAPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDG
NILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQ
SALSKDPNEKRDHMLLEFVTAAGITLGMDELYKLPETGGLEHHHHHH

HPLC procedures were performed on an Auno High-Performance Liquid Chromatography System (P2010 high pressure infusion pump; UV (190-400 nm) detector; 7725i manual injection valve; *Easychrom* chromatography workstation) using the Dr. Maisch GmbH packed reversed-phase column (ReproSil-Pur Basic-C18, 5 μm, 250×4.6 mm for analysis; ReproSil-Pur Basic-C18, 5 μm, 250×10 mm for purification, respectively).

NMR (¹H NMR/¹³C NMR/¹⁹F NMR) spectrum were recorded on Bruker 400MHz or Bruker 500MHz NMR or Bruker 600MHz NMR spectrophotometer. High resolution mass spectroscopy was recorded on Bruker Solarix XR

mass spectrometer or AB Sciex 5800 MALDI-TOF mass spectrometer. IR spectra were recorded on a Bruker Tensor 27 FTIR Spectrometer.

UV-vis spectra were conducted on an Agilent Cary 8454 UV-vis spectrometer equipped with an Agilent 89090A thermostat (± 0.1 °C) at 25 °C. The emission spectra were obtained on an Edinburgh Analytical Instruments FLS980 lifetime and steady state spectrometer (450 W Xe lamp/60 W microsecond flash lamp, PMT R928 for visible emission spectrum, HAMAMATSU R5509-73 PMT with C9940-02 cooler for NIR emission spectrum and luminescence lifetime). The excited state lifetime decay curves were obtained on an Edinburgh LifeSpec II picosecond time-resolved fluorescence spectrometer (260-1100 nm laser, 77-500K variable temperature, and MCP detector). All animal procedures were approved by the Institutional Animal Care and Use Committee of Sinoresearch (Beijing) Biotechnology Co., Ltd. (protocol number: 20211205)

Methods.

General procedures

General procedure 1 for β -fluoropyrrolyl-cysteine S_NAr chemistry between P_4 and peptides. P_4 was dissolved in water to prepare a stock solution (100 mM). 500 μ L Tris buffer (pH 8.0), P_4 (5 μ L, 100 mM), and corresponding peptide in H₂O or DMSO (2.5 μ L, 50 mM) was successively added to a 1 mL centrifuge tube, and stirred for 15 min in dark. The reaction mixture was quenched by 5 μ L trifluoroacetic acid (TFA). The crude mixture was analysed on analytical HPLC with **Method B** (ReproSil-Pur Basic-C18, 5 μ m, 250 \times 4.6 mm) and major peaks were identified by high resolution mass spectroscopy (HRMS). The yield of P_4 -a was determined according to calibrated HPLC integral area using the formula:

$$\text{Yield (P}_4\text{-a)} = \frac{4N(\text{P}_4\text{-a})}{N(\text{P}_4\text{-a})+N(\text{P}_4\text{-2a})+N(\text{P}_4)}$$

$N(\text{P}_4)$: final content of P_4 (nM); $N(\text{P}_4\text{-a})$: final content of P_4 -a (nM); $N(\text{P}_4\text{-2a})$: final content of P_4 -2a (nM).

The product was isolated by reverse phase RP-HPLC system with **Method C** (ReproSil-Pur Basic-C18, 5 μ m, 250 \times 10 mm).


General procedure 2 for β -fluoropyrrolyl-cysteine S_NAr chemistry between β -octafluoroporphyrins (P_{4-II}) and glutathione (GSH). β -octafluoroporphyrin was dissolved in water to prepare a stock solution (100 mM). 500

μL Tris buffer (pH 8.0), β -octafluoroporphyrin (5 μL , 100 mM), and GSH in H_2O (2.5 μL , 50 mM) was successively added to a 1 mL centrifuge tube, and stirred for 15 min in dark. The reaction mixture was quenched by 5 μL TFA. The crude mixture was analysed on analytical HPLC with **Method B** (ReproSil-Pur Basic-C18, 5 μm , 250 \times 4.6 mm) and major peaks were identified by HRMS. The yield was determined as described above.


The product was isolated by reverse phase RP-HPLC system with **Method C** (ReproSil-Pur Basic-C18, 5 μm , 250 \times 10 mm).

Synthesis of substrates.

2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin




A solution of *p*-xylene dibromide (8 g, 30 mmol) and activated manganese dioxide (12 g, 140 mmol) in chloroform (300 mL) was refluxed for 3 days. The reaction mixture was filtered and washed with chloroform. The combined filtrates were evaporated and separated on silica gel using petroleum ether-dichloromethane (3:1) as eluent. The product (1.2 g, 20%) was obtained as a white solid.




3,4-Difluoropyrrole (206 mg, 2.0 mmol) and 4-bromomethylbenzaldehyde (400 mg, 2.0 mmol) were dissolved in 400 mL anhydrous dichloromethane (DCM). The mixture was stirred for 5 min, then boron trifluoride etherate (BF₃ · Et₂O) (100 μ L) was added. The mixture was then stirred for 2 h at room temperature. 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (476 mg, 2.1 mmol) was added. After stirring for 2 h, the reaction mixture was transferred to a silica flash column and eluted by DCM. The obtained solution was evaporated *in vacuo* and isolated on silica gel column with petroleum ether/dichloromethane (v/v = 3:1) as eluent to give dark brown 2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin (150 mg, 66%). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.01 (d, *J* = 8.0 Hz, 8H), 7.75 (d, *J* = 8.0 Hz, 8H), 4.80 (s, 8H), -4.18 (s, 2H). ¹⁹F NMR (471 MHz, Chloroform-*d*) δ -140.03 (s, 4F), -145.14 (s, 4F). HRMS (MALDI-FTICR), [M+H]⁺ calcd. For [C₄₈H₂₇Br₄F₈N₄]⁺ 1126.8836; Found: 1126.8805.

2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(α -pyridinio-*p*-tolyl)porphyrin (**P**₄)



2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin (115 mg, 0.1 mmol), pyridine (79 mg, 1 mmol) was dissolved in 5 mL CH₃CN in a Schlenk tube and refluxed at 90 °C for 24 h. After cooling to room temperature, the reaction mixture was filtered and the solid residue was washed with DCM (5 mL × 3), acetone (5 mL × 3), hexane (5 mL × 3) to give crude product as dark solid. Furthermore, the crude compound was purified by RP-HPLC using **Method C** to give the desired compound **P**₄ as a dark brown solid (82 mg, 73%). ¹H NMR (500 MHz, Methanol-*d*₄) δ 9.40 (d, J = 5.5 Hz, 4H), 8.81 (t, J = 7.9 Hz, 2H), 8.40 – 8.33 (m, 3H), 8.27 (d, J = 8.1 Hz, 3H), 7.96 (d, J = 8.1 Hz, 3H), 6.28 (s, 3H). ¹³C NMR (126 MHz, Methanol-*d*₄) δ 146.32, 144.94, 138.60, 133.21, 128.66, 127.79, 64.33. ¹⁹F NMR (471 MHz, Methanol-*d*₄) δ -142.89 (s, 4F), -148.50 (s, 4F). HRMS (ESI⁺-FTICR) m/z [M^{4+} -H⁺] calcd. for C₆₈H₄₅F₈N₈ 375.1208 found: 375.1206; [M^{4+}] calcd. for C₆₈H₄₆F₈N₈ 281.5924 found: 281.5922


2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(N, N', N''-trimethylammonium-*p*-tolyl)porphyrin (**P**₅)



2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin (38 mg, 0.033 mmol), 33% trimethylamine ethanol solution (0.5 mL) was dissolved in CH₃CN/MeOH (3 mL, v/v = 2:1) in a Schlenk tube and


stirred at 50 °C for 12 h. After cooling to room temperature, the reaction mixture was evaporated *in vacuo* to give crude product as dark solid. Furthermore, the crude compound was purified by RP-HPLC using **Method C** to give the desired product **P₅** as dark brown solid (29 mg, 85%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.37 (s, 8H), 8.05 (s, 8H), 4.94 (s, 8H), 3.37 (d, *J* = 5.8 Hz, 36H). ¹⁹F NMR (471 MHz, Methanol-*d*₄) δ -142.81 (s, 4F), -148.37 (s, 4F). HRMS (ESI⁺-FTICR) *m/z* [M⁴⁺] calcd. for C₆₀H₆₂F₈N₈ 261.6228 found: 261.6234.

2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(N-benzyl-2-hydroxy-N,N-dimethylethanammonium) porphyrin (P₆)



2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin (38 mg, 0.033 mmol), newly distilled 2-(N, N-dimethylamino)ethanol (1 mL) was dissolved in CH₃CN/MeOH (3 mL, v/v = 2:1) in a Schlenk tube and stirred at 50 °C for 12 h. After cooling to room temperature, the reaction mixture was evaporated *in vacuo* and the oily solid residue was purified by RP-HPLC using **Method C** to give the desired product **P₆** as a dark brown solid (25 mg, 65%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.34 (d, *J* = 7.3 Hz, 8H), 8.06 (d, *J* = 7.4 Hz, 8H), 5.03 (s, 9H), 4.27 (s, 8H), 3.75 (s, 8H), 3.38 (s, 23H). ¹⁹F NMR (471 MHz, Methanol-*d*₄) δ -142.77 (s, 4F), -148.33 (s, 4F). HRMS (ESI⁺-FTICR) *m/z* [M⁴⁺-H⁺] calcd. for C₆₄H₆₉F₈N₈O₄³⁺ 388.5099 found: 388.5103; [M⁴⁺] calcd. for C₆₄H₇₀F₈N₈O₄⁴⁺ 291.6343 found: 291.6338.


2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(benzyl-[2-(2-hydroxyethoxy)ethyl]-dimethylazanium) porphyrin (P₇)



The synthetic procedure of **P₇** is similar to that of **P₆** by using corresponding newly distilled 1-O-dimethylaminoethyl-ethylenglykol.


2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin (38 mg, 0.033 mmol), newly distilled 1-O-dimethylaminoethyl-ethylenglykol (1 mL) was dissolved in CH₃CN/MeOH (3 mL, v/v = 2:1) in a Schlenk tube and stirred at 50 °C for 12 h. After cooling to room temperature, the reaction mixture was evaporated *in vacuo* and the oily solid residue was purified by RP-HPLC using **Method C** to give the desired product compound **P₇** as a dark brown solid (32 mg, 71%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.31 (d, *J* = 8.2 Hz, 8H), 8.04 (d, *J* = 8.2 Hz, 8H), 5.00 (s, 8H), 4.17 (s, 8H), 3.86 – 3.79 (m, 16H), 3.76 – 3.71 (m, 8H), 3.35 (s, 24H). ¹⁹F NMR (471 MHz, Methanol-*d*₄) δ -142.78 (s, 4F), -148.37 (s, 4F). HRMS (ESI⁺-FTICR) *m/z* [M⁴⁺] calcd. for C₇₂H₈₆F₈N₈O₈⁴⁺ 335.6605 found: 335.6604; [M⁴⁺-H⁺] calcd. for C₇₂H₈₅F₈N₈O₈³⁺ 447.2115 found: 447.2115; [M⁴⁺-H⁺+CF₃COOH] calcd. for C₇₄H₈₆F₁₁N₈O₁₀³⁺ 485.2092 found: 485.2093.

2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(benzyltrimethyl(2-propynyl)ammonium)porphyrin (P**₈)**




2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin (38 mg, 0.033 mmol), newly distilled N,N-Dimethylpropargylamine (1 mL) was dissolved in CH₃CN/MeOH (3 mL, v/v = 2:1) in a Schlenk tube. The reaction mixture was degassed at -78 °C and flushed with nitrogen for three times. After stirring at room temperature for 12 h, the reaction mixture was evaporated *in vacuo* and the dark brown solid residue was purified by RP-HPLC using **Method C** to give the desired product compound **P**₈ as a dark brown solid (18 mg, 47%). **P**₈ was stored in -20 °C refrigerator for following experiments. ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.40 (d, *J* = 7.9 Hz, 8H), 8.11 (d, *J* = 8.0 Hz, 8H), 5.06 (s, 8H), 4.54 (s, 8H), 3.84 (s, 4H), 3.45 (s, 24H). ¹⁹F NMR (471 MHz, Methanol-*d*₄) δ -142.80 (s, 4F), -148.36(s, 4F). HRMS (ESI⁺-FTICR) *m/z* [M⁴⁺] calcd. for C₆₆H₆₂F₈N₈⁴⁺ 285.6237 found: 285.6233; [M⁴⁺-H⁺] calcd. for C₆₆H₆₁F₈N₈³⁺ 380.4958 found: 380.4959.

2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(benzyltrimethyl(2-azido)ammonium)porphyrin (P**₉)**




2-chloro-N,N-dimethylethan-1-amine hydrochloride (1.4 g, 10.0 mmol) was dissolved in deionized water (40 mL), and then add sodium azide (1.9 g, 30.0 mmol). The mixture was stirred at 80 °C for 24 h. The reaction mixture was cooled to room temperature, the pH of the solution was adjusted to 10 using 1M NaOH solution, and extracted with dichloromethane for three times. Organic layer was collected and dried with anhydrous Na₂SO₄. Finally, extract was evaporated *in vacuo* to give 2-azido-N, N-dimethylethan-1-amine as a colorless oil (0.98 g, 85 %). ¹H NMR (400 MHz, Chloroform-*d*) δ 3.31 (t, *J* = 6.1 Hz, 1H), 2.46 (t, *J* = 7.0 Hz, 1H), 2.23 (s, 3H). HRMS (ESI⁺-FTICR) *m/z* [M+H]⁺ calcd. for C₄H₁₁N₄⁺ 115.0978 found: 115.0978.



2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin (38 mg, 0.033 mmol), newly distilled 2-azido-N,N-dimethylethan-1-amine (0.2 mL) was dissolved in CH₃CN/MeOH (3 mL, v/v = 2:1) in a Schlenk tube. The reaction mixture was stirred at 50 °C for 6 h, then the solution was evaporated *in vacuo* and the dark brown solid residue was purified by RP-HPLC using **Method C** to give the desired product compound **P₉** as dark brown solid (21 mg, 51%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.32 (d, *J* = 7.7 Hz, 8H), 8.01 (d, *J* = 7.8 Hz, 8H), 4.95 (s, 8H), 4.19 (t, *J* = 5.0 Hz, 8H), 3.86 – 3.73 (m, 8H), 3.32 (s, 24H). ¹⁹F NMR (471 MHz, Methanol-*d*₄) δ -142.70 (s, 4F), -148.29 (s, 4F). HRMS (ESI⁺-FTICR) *m/z* [M⁴⁺] calcd. for C₆₄H₆₆F₈N₂₀⁴⁺ 316.6407 found: 316.6405; [M⁴⁺-H⁺] calcd. for C₆₄H₆₅F₈N₂₀³⁺ 421.8519 found: 421.8524.

2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(benzyltrimethyl phosphonium)porphyrin (**P₁₀**)




2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin (38 mg, 0.033 mmol), newly distilled trimethylphosphane (1 mL) was dissolved in N, N-dimethylformamide (DMF) in a Schlenk tube. The reaction mixture was degassed at -78 °C and flushed with nitrogen for three times. After stirring at 90 °C for 12 h, the solvent was distilled *in vacuo* and the dark brown solid residue was purified by RP-HPLC using **Method C** to

give the desired product compound **P₁₀** as dark brown solid (27 mg, 74%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.24 (d, *J* = 7.7 Hz, 8H), 7.78 (d, *J* = 10.7 Hz, 8H), 4.11 (d, *J* = 16.2 Hz, 8H), 2.06 (d, *J* = 14.3 Hz, 36H). ¹⁹F NMR (565 MHz, Methanol-*d*₄) δ -143.18 (s, 4F), -148.73 (s, 4F). HRMS (ESI⁺-FTICR) *m/z* [*M*⁴⁺] calcd. for C₆₀H₆₂F₈N₄P₄⁴⁺ 278.5944 found: 278.5944; [*M*⁴⁺-H⁺] calcd. for C₆₀H₆₂F₈N₄P₄³⁺ 371.1234 found: 371.1244.

2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(benzyldimethylsulfonium)porphyrin


(P₁₁)




2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin (38 mg, 0.033 mmol), dimethylsulfane (1 mL) was dissolved in CH₃CN/MeOH (3 mL, v/v = 2:1) in a Schlenk tube. The reaction mixture was degassed at -78 °C and flushed with nitrogen for three times. After stirring at room temperature for 48 h, the solvent was distilled *in vacuo* and the dark brown solid residue was purified by RP-HPLC using **Method C** to give the desired product compound **P₁₁** as a dark brown solid (16 mg, 46%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.28 (d, *J* = 8.1 Hz, 8H), 7.90 (d, *J* = 8.1 Hz, 8H), 4.97 (s, 8H), 3.03 (s, 24H). ¹⁹F NMR (471 MHz, Methanol-*d*₄) δ -142.94 (s, 4F), -148.52 (s, 4F). HRMS (ESI⁺-FTICR) *m/z* [*M*⁴⁺] calcd. for C₅₆H₅₀F₈N₄S₄⁴⁺ 264.5692 found: 264.5688.

2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(3-(2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy)-phenyl)porphyrin (P₁₂)

3-(2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy)-benzaldehyde




3-hydroxybenzaldehyde (1.22 g, 10 mmol), 1-bromo-2-(2-(2-methoxyethoxy)ethoxy)ethane (3.4 g, 15 mmol), and K_2CO_3 (4.14 g, 30 mmol) were mixed in DMF (20 mL). The reaction mixture was degassed at $-78\text{ }^\circ\text{C}$ and flushed with nitrogen for three times, then refluxing at $150\text{ }^\circ\text{C}$ for 5 days. After cooling to room temperature, the solvent was distilled *in vacuo* to give crude product 3-(2-[2-(2-methoxyethoxy)-ethoxy]-ethoxy)-benzaldehyde as the faint yellow oil. Furthermore, it was purified using reversed phase column with MeOH/ H_2O (v/v from 20%/80%-60%/40%) on Biotage Isolera Prime (1.9 g, 72%). 1H NMR (400 MHz, Chloroform-*d*) δ 9.97 (s, 1H), 7.44 (s, 2H), 7.41 (s, 1H), 7.21 (d, $J = 7.2$ Hz, 1H), 4.20 (s, 2H), 3.89 (s, 2H), 3.75 (s, 2H), 3.68 (d, $J = 16.9$ Hz, 4H), 3.56 (s, 2H), 3.38 (s, 3H). HRMS (ESI⁺-FTICR) m/z $[M+Na^+]$ calcd. for $C_{14}H_{20}NaO_5^+$ 291.1203 found: 291.1196.



3,4-Difluoropyrrole (206 mg, 2.0 mmol) and 3-(2-[2-(2-methoxyethoxy)-ethoxy]-ethoxy)-benzaldehyde (540 mg,


2.0 mmol) were dissolved in 400 mL anhydrous dichloromethane (DCM). The mixture was stirred for 5 min after which, boron trifluoride etherate ($\text{BF}_3 \cdot \text{Et}_2\text{O}$) (100 μL) was added. The mixture was then stirred for 12 h at room temperature. 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (475 mg, 2.1 mmol) was added. After reacting for 2 h, the reaction mixture was transferred to a silica flash column and eluted by ethyl acetate. The obtained solution was evaporated *in vacuo* and isolated on silica gel column with petroleum ether/ethyl acetate (v/v, 90%/10%-1%/99%) as eluent on Biotage Isolera Prime to give dark brown **P**₁₂ (81 mg, 29%). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.63 (s, 12H), 7.35 (s, 4H), 4.32 (s, 8H), 3.94 (s, 8H), 3.78 (s, 8H), 3.69 (s, 8H), 3.64 (s, 8H), 3.51 (s, 8H), 3.33 (s, 12H), -4.23 (s, 2H). ¹⁹F NMR (471 MHz, Chloroform-*d*) δ -140.26 (s, 4F), -145.29 (s, 4F). HRMS (ESI⁺-FTICR) *m/z* [M+H⁺] calcd. for C₇₂H₇₉F₈N₄O₁₆⁺ 1407.5358 found: 1407.5340; [M+H⁺+NH₄⁺] calcd. for C₇₂H₈₃F₈N₅O₁₆²⁺ 712.7848 found: 712.7851.

2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(2,6-difluorophenyl)porphyrin



3,4-Difluoropyrrole (206 mg, 2 mmol), 2,6-difluorobenzaldehyde (285 mg, 2 mmol), and anhydrous DCM (300 mL) were mixed under N₂ in a 500 mL round-bottom flask. Boron trifluoride etherate ($\text{BF}_3 \cdot \text{Et}_2\text{O}$) (200 μL) was dropped slowly into the mixture and the resulting solution was stirred for 2 h. Then, DDQ (400 mg, 2 mmol) was added. The reaction mixture was stirred overnight and eluted through a flash silica gel column with DCM/petroleum ether (v/v = 1:5). The solvent was removed under reduced pressure, and the crude product was chromatographed through a silica gel column with DCM/petroleum ether (v/v, 1:50) to give desired product 2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis(2,6-difluorophenyl)porphyrin (80 mg, 44%) as dark brown solid. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.78 (p, $J = 7.4$ Hz, 4H), 7.34 (t, $J = 7.5$ Hz, 8H), -4.13 (s, 2H). ¹⁹F NMR (471 MHz, Chloroform-*d*) δ -110.62 (s, 8F), -144.31 (s, 4F), -149.60 (s, 4F). HRMS (ESI⁺-FTICR) *m/z* [M+H⁺] calcd. for C₄₄H₁₅F₁₆N₄, [M+H⁺]: 903.1036; Found: 903.1036.

2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(3-sulfonato-2,6-difluorophenyl)porphyrin (P₁₃)



2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(2,6-difluorophenyl)porphyrin was dissolved (50 mg, 0.055 mmol) in fuming H₂SO₄ (18-20% free SO₃, 1 mL) and heated at 80 °C for 1 h. The mixture was cooled to room temperature before carefully adding H₂O (20 mL). After neutralization with 1 M NaOH aqueous solution, the solvent was removed *in vacuo*. Followingly, the remaining solid was dissolved in CH₃OH and filtered to remove excessive Na₂SO₄. The desired product **P₁₃** (54 mg, 80%) was precipitated from CH₃OH by adding anhydrous diethyl ether into the solution. ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.40 (q, *J*=8.3, 4H), 7.54 (tt, *J*=8.1, 3.1, 4H). ¹⁹F NMR (471 MHz, Methanol-*d*₄) δ -108.67 (br, 4F), -109.30 – -109.50 (m, 4F), -146.43 (s, 4F), -151.59 (s, 4F). HRMS (ESI-FTICR), [M-3H]³⁻ calcd. For [C₄₄H₁₁F₁₆N₄O₁₂S₄]³⁻ 406.4006; Found: 406.3007; [M-4H]⁴⁻ calcd. for [C₄₄H₁₀F₁₆N₄O₁₂S₄]⁴⁻ 304.4736; Found: 304.4739.

Computational details. In this work, we performed geometry optimizations for ground (S_0) and excited states (S_1 , T_1 - T_4) followed by harmonic vibrational frequencies calculation with hybrid density functional, B3LYP⁴ with “D3BJ”⁵ dispersion corrections, using the program package Gaussian 09 (Revision E.01).^{4,5,6} The 6-311G(d) basis set^{5,6} was used for all atoms. Solvent effects (including the geometry optimizations and frequencies) were considered by means of SMD^{7,8,9} model for dichloromethane to match the experimental conditions. Frequency calculations were performed on the optimized structures to ensure that they were in minimum energy structures by the absence of imaginary frequency. Stability calculations were also performed for all the optimized structures to ensure that all the wavefunctions were stable.

The spin-orbit coupling (SOC) constants between the spin states of S_1 and T_n , $\langle T_n | \hat{H} | S_1 \rangle$, were estimated using effective atomic charge (Zeff) method by PySOC^{8,9} following the guidance in <http://sobereva.com/411>. The intersystem crossing rate constants (k_{ISC}) were calculated by MOMAP program package¹⁰⁻¹⁴ using a thermal vibration correlation function formalism for the transition between two adiabatic electronic states considering displacements, distortions, and Duschinsky rotations of potential energy surfaces within the framework of multidimensional harmonic oscillator model and Franck-Condon principle.

Reaction rate. For the kinetic study, compound **P₄** (1 mM, 1.126 mg/mL in ultrapure water stock solution) and GSH (1 mM, 0.307 mg/mL in ultrapure water stock solution) were reacted in 1000 μ L Tris buffer (pH 8.0) at room temperature. At certain time point (e. g. 1 min, 3 min, 5 min, 7 min, 9 min, 11 min, 13 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min, 50 min, 55 min, 60 min, 70 min, and 80 min), 20 μ L of reaction mixture was withdrawn and immediately quenched by 1 μ L trifluoroacetic acid. After that, the mixture was frozen before injecting to analytical HPLC. HPLC analysis clearly indicated that the peak for compound **P₄** gradually decreased while the peak for conjugates increased. The quantification was obtained based on the calibrated integration of the absorbance peak of compound **P₄** and conjugates at 395 nm, which correspond to the conversion during the reaction progress.

The rate constant k of the reaction between compound **P₄** and GSH was obtained based on the second-order reaction kinetics. The rate constant k was determined by the following formula:

$$\frac{1}{[A]} = \frac{1}{[A_0]} + kt$$

[A]: real-time concentration of **P₄**, [A₀]: initial concentration of compound **P₄** (1 mM), k : rate constant


Based on the HPLC analysis, $\frac{1}{[A]}$ over time was linearly-plotted which is shown in **Figure S12** and the slope is the rate constant ($1.44 \text{ M}^{-1} \cdot \text{s}^{-1}$).

P₁₂ reacted with GSH. P₁₂ was dissolved in dimethylsulfoxide (DMSO) to prepare a stock solution (100 mM). 242.5 μL Tris buffer (pH 8.0), 250 μL DMSO, P₁₂ (5 μL, 100 mM), and GSH in H₂O (2.5 μL, 50 mM) was successively added to a 1 mL centrifuge tube, and stirred for 15 min in dark. After that, the reaction mixture was quenched by 5 μL TFA. The crude mixture was analysed on analytical HPLC with **Method D** (ReproSil-Pur Basic-C18, 5 μm, 250×4.6 mm) and major peaks were identified by HRMS.

P₁₃ reacted with GSH. P₁₃ was dissolved in H₂O to prepare a stock solution (100 mM). 490 μL Tris buffer (pH 8.0), P₁₃ (5 μL, 100 mM), and GSH in H₂O (5 μL, 200 mM) was successively added to a 1 mL centrifuge tube, and stirred for 15 min in dark. After that, the reaction mixture was quenched by 5 μL TFA. The crude mixture was analysed by UV-vis spectrometer and HRMS, respectively.

Click chemistry.

Strain-promoted azide-alkyne cycloaddition (SPAAC) between β-peptidyl azido-porphyrin (**P₉-a**) and dibenzocyclooctyne reagent (**h/i/j**).



In a 0.2 mL centrifuge tube, β-peptidyl azido-porphyrin (**P₉-a**) in H₂O (1.00 μL, 20.0 mM) and dibenzocyclooctyne reagent (**h/i/j**) in DMSO (1.1 μL, 80 mM, 4.4 equiv.) were combined. The resulting mixture was stirring for 30 minutes at room temperature. After that, the reaction mixture was diluted with H₂O (17.9 μL) and analyzed by HPLC. The desired products **P₉-ah/i/j** were confirmed by HRMS (ESI⁺-FTICR).

Protein bioconjugation.

P₄/P₈/P₁₃ (0.5 μL, 100 mM), protein (5 μL, 0.5 mM in 1×PBS), and NaCl (10 μL, 5 M) were mixed in a Tris buffer (34.5 μL, pH 8.0) and reacted at room temperature for 8 h. After that, the solution was desalted by passing through

Bio-Rad desalting column (10 K) to give corresponding protein conjugate, respectively. The protein conjugate was analyzed by MALDI-TOF and SDS-PAGE gel (in gel fluorescence and coomassie brilliant blue staining).

Streptavidin (Sav, 5 μ L, 10 mg/mL in 1 \times PBS), 2-iminothiolane hydrochloride (Traut's reagent, 0.42 μ L, 20 mM in H₂O) were mixed in Tris buffer (44.6 μ L, pH 8.0). The mixture was incubated at 25 $^{\circ}$ C for 60 min before removing all the unreacted Traut's reagent by passing through Bio-Rad desalting column (10 K). The obtained solution was mixed with **P**₁₃ (0.42 μ L, 20 mM in H₂O), incubated at 4 $^{\circ}$ C overnight, and then desalted. MALDI-TOF indicated a complete conversion of Sav into **P**₁₃-Sav.

EGFP (5 μ L, 0.5 mM 1 \times PBS), and iodoacetamide (**IAA**, 0.63 μ L, 20 mM in H₂O) were mixed in Tris buffer (44.4 μ L, pH 8.0) and reacted at room temperature for 1 h. After that, the solution was desalted to give **IAA-EGFP**.

Synthesis of P₁₃-EGFP-PDS and IAA-EGFP-PDS. The neutralized stock lipoic acid (LA) solution with a final concentration of 100 mM was prepared by dissolving lipoic acid (206.33 mg, 1.0 mmol) with stoichiometric NaOH in an aqueous solution (0.1 M in 10 mL). The pH of the LA solution was then carefully adjusted to 7.0. Next, EGFP solution (2 μ L, 25 mg/mL) was added to the freshly prepared LA solution (48 μ L, 100 mM) and the mixture was incubated at -30 $^{\circ}$ C for 2 h. The reaction was quenched with **P**₁₃ or **IAA** (10 μ L, 100 mM in H₂O) at room temperature for 30 min. The result was evidenced by non-reducing (DTT free) SDS-PAGE gel analysis (Coomassie brilliant blue staining).

Metabolic labeling of Sialoglycoproteins. For O-GlcNAc labeling, HeLa cells were incubated with 50 μ M Ac₄ManNAz for 48 h. The cells were fixed with 4% (w/v) formaldehyde in 1 \times PBS for 15 min, washed three times with 1 \times PBS. After three washes with 1 \times PBS, the cells were incubated with 50 μ M biotin-PEG4-alkynyl, THPTA-CuSO₄ complex (50 μ M CuSO₄, THPTA/CuSO₄ 6:1, mol/mol) and 2.5 mM sodium ascorbate in PBS at room temperature for 30 min, followed by three washes with 0.1% (v/v) Tween 20 in 1 \times PBS. The cells were then incubated with 5 μ g/ml **P**₁₃-Sav in 1 \times PBS containing 1% (w/v) BSA for 1 h and washed three times with PBS for confocal microscopy.

Measurement of ¹O₂ generation efficiency. The singlet oxygen generated by compound **P**₄, **P**_{4-a}, and **P**_{4-2a} were measured using 1, 3-diphenylisobenzofuran (DPBF). The relative quantum yields were calculated with that of the standard reference (tetraphenylporphyrin, TPP) in toluene. Briefly, an oxygen-saturated solution of photosensitizer containing 4 μ M DPBF was prepared in the dark. Then, the cuvette was irradiated with a 405 nm laser at 5 mW/cm² for 60 s. Φ_{Δ} was calculated by the following equation:

$$\Phi_{\Delta sam} = \Phi_{\Delta std} \frac{k_{sam}}{k_{std}} \frac{F_{std}}{F_{sam}}$$

Where “*sam*” and “*std*” represent the “complex” and “TPP”, respectively. “*k*” is the slope of absorbance change curve of DPBF at 415 nm, $F=1-10^{-OD}$ (OD is the absorbance of the solution at 405 nm).

Cytotoxicity evaluation *in vitro*. CCK-8 assay was carried out to evaluate the dark toxicity and phototoxicity of compound **P₄**, **P_{4-a}**, and **P_{4-2a}**. HeLa cells were seeded into 96-well plates at the density of 1×10^4 per well and incubated at 37 °C for 24 h. After removal of the medium and rinsing with PBS, HeLa cells were pretreated with compound **P₄**, **P_{4-a}**, and **P_{4-2a}** (final concentration contains 0, 0.25, 0.5, 1, 2 or 4 μM), respectively. One plate was kept in the dark for studying dark toxicity, and another plate was irradiated using the 400-700 nm laser at a power of 10 mW cm⁻² for 10 min. All group cells were incubated for another 24 h, the cell viability was detected by added of Cell Counting Kit-8 (CCK-8, 10 μL), and the absorbance at a wavelength of 450 nm of each well was measured using a 96-well plate reader. The cell viability was then determined *via* the following equation: cell viability (%) = (mean of abs. value of treatment group/mean abs. value of control) × 100%.

Cellular internalization measured by confocal laser scanning microscopy (CLSM). HeLa cells were seeded in a cell culture chamber and incubated for 24 h at 37 °C in 5% CO₂ before the experiment. After medium aspiration, the cells were incubated with EGFP (250 nM × 200 μL) or **P₁₃-EGFP** (250 nM × 200 μL) or **P₁₃-EGFP-PDS** (250 nM × 200 μL) for 1 h at 37 °C before three 1×PBS washes. Next, HeLa cells were fixed with 4% PFA, then co-stained with Hoechst 33258 for 5 min, washed and reintroduced with PBS buffer (1×, pH = 7.4) and imaged with CLSM.

Enzymatic assay of caspase-3 in solutions. The enzymatic assays were first carried out with a recombinant caspase-3 solution. The mixtures of the probe (**P_{4-k}**, 10 μM) and caspase-3 (150 ng/mL) were incubated in PBS buffer (1×, pH = 7.4) at 37 °C in a centrifuge tube for 1 h. Then, the reaction solution was transferred to a cuvette with 1 cm optical length for fluorescence measurements excited by 470 nm. In the meantime, the blank solution without caspase-3 and the inhibition solution with caspase-3 inhibitor (5-[(S)-(+)-2-(methoxymethyl)pyrrolidino]sulfonylisatin, 5 μM) was also measured under the same condition for comparison.


Fluorescence imaging of caspase-3 in live HeLa cells. **P_{4-k}** was diluted with DMEM to work concentration (10 μM). For untreated HeLa cells, probe solution (**P_{4-k}**) was added to the chamber and incubating at 37 °C for 1 h, then washed twice with PBS buffer (1×, pH = 7.4), and kept in fresh FBS-free DMEM for observation under a microscope. For apoptotic cells, the cells were first treated with 3 μM apoptosis inducer STS for 1 h. After washing twice with PBS buffer (1×, pH = 7.4), probe solution (**P_{4-k}**) was added and incubated at 37 °C for 1 h. After washing twice with PBS buffer (1×, pH = 7.4), the STS-treated cells were kept in fresh FBS-free DMEM for

observation under a microscope. For apoptotic inhibited cells, the cells were first incubated with 3 μM apoptosis inducer STS and 5 μM apoptosis inhibitor (5-[(S)-(+)-2-(methoxymethyl)pyrrolidino] sulfonylisatin) for 2 h. After washing twice with PBS buffer (1 \times , pH = 7.4), probe solution (**P₄-k**) was added and incubated at 37 $^{\circ}\text{C}$ for 1 h. After washing twice with PBS buffer (1 \times , pH = 7.4), the STS-treated cells were kept in fresh FBS-free DMEM for observation under a microscope. Confocal fluorescence microscopy of live cells was performed using an ISS Alba5 FLIM/FFS confocal system equipped with a Nikon TE2000 inverted microscope, and a 488 nm laser using the Semrock 525/50 nm band pass filters.


Fluorescence imaging of A549/MCF7. For A549, **P₄** or **P₄-a** or **P₄-f** was diluted with DMEM to work concentration (8 μM). For untreated A549 cells, probe solution (**P₄** or **P₄-a** or **P₄-f**) was added to the chamber and incubating at 37 $^{\circ}\text{C}$ for 30 min, the cells were washed twice with PBS buffer (1 \times , pH = 7.4) and kept in fresh FBS-free DMEM for observation under a microscope. For iRGD inhibited group, cells were incubated with iRGD (20 μM) for 1 h, then incubated with **P₄-f** (8 μM) at 37 $^{\circ}\text{C}$ for 30 min, washed twice with PBS buffer (1 \times , pH = 7.4), and kept in fresh FBS-free DMEM for observation under a microscope. Quantitative relative fluorescence intensity of A549 and MCF7 was analysed via ImageJ software.

For MCF7, fluorescence imaging of MCF7 cells was performed in the same experimental protocol as A549.

***In vivo* photodynamic therapy assay.** The dosage of 2 mg/kg body weight for A549 tumor mice model was selected. A549 cells at 1×10^6 in 100 μL of serum-free medium was injected into the right back of SCID female mice. When the average tumor volume reached about 20 mm^3 after 15 days, mice were randomly divided into four groups (3 mice/group) for the control group (PBS+light (white light, $100 \text{ mW} \cdot \text{cm}^{-2}$, 10 min)), **P₄** treatment group, **P₄**+light (white light, $100 \text{ mW} \cdot \text{cm}^{-2}$, 10 min) group, **P₄-f**+light (white light, $100 \text{ mW} \cdot \text{cm}^{-2}$, 10 min), and **P₄-a**+light (white light, $100 \text{ mW} \cdot \text{cm}^{-2}$, 10 min) group. Mice were treated with 100 μL PBS or 2 mg/kg body weight of corresponding compounds by i.v. injection at the first day. After the 2 h post-injection, mice were exposed to white light at a density of $100 \text{ mW} \cdot \text{cm}^{-2}$ for 10 min. Tumor volume was calculated using the formula: volume = $(L \times W \times W)/2$, with “L” refers to the maximal length of tumors and “W” being the width. At the end of the experiments, the tumor tissues and major organs of each group were harvested. The tumor and organ sections were subjected to Hematoxylin and eosin (H&E) staining.




P₄-c: ¹H NMR (600 MHz, Deuterium Oxide, 1%MeOH) δ 9.11 – 9.05 (m, 6H), 9.00 (d, *J* = 5.7 Hz, 2H), 8.63 – 8.42 (m, 11H), 8.33 (s, 1H), 8.14 (t, *J* = 7.2 Hz, 6H), 8.10 – 8.05 (m, 2H), 7.90 (d, *J* = 8.0 Hz, 7H), 7.80 (d, *J* = 7.8 Hz, 1H), 6.99 (s, 3H), 6.78 (s, 2H), 6.11 (s, 6H), 6.01 (s, 2H), 4.17 (s, 1H), 3.77 (q, *J* = 7.1 Hz, 1H), 3.58 (d, *J* = 3.3 Hz, 2H), 3.16 – 3.13 (m, 1H), 2.84 – 2.68 (m, 3H), 2.49 (s, 1H), 0.69 (d, *J* = 7.1 Hz, 3H). ¹³C NMR (151 MHz, Deuterium Oxide, 1%MeOH) δ 173.17, 163.30, 147.06, 145.32, 143.62, 138.20, 136.57, 135.75, 132.36, 129.35, 127.66, 121.43, 120.55, 120.15, 119.77, 119.24, 117.84, 115.90, 113.97, 64.92, 52.16, 49.50, 35.44, 16.96. ¹⁹F NMR (565 MHz, Deuterium Oxide, 1%MeOH) δ -124.74, -145.05 – -147.83 (m). HRMS (ESI⁺-FTICR) *m/z* [*M*⁴⁺] calcd. for C₈₅H₆₉F₇N₁₂O₅S⁴⁺ 375.6275 found: 375.6270; [*M*⁴⁺-H⁺] calcd. for C₈₅H₆₈F₇N₁₂O₅S³⁺ 500.5009 found: 500.5012; [*M*⁴⁺-H⁺+TFA] calcd. for C₈₇H₆₉F₁₀N₁₂O₇S³⁺ 538.4986 found: 538.4997.




P₄-d: HRMS (ESI⁺-FTICR) *m/z* [*M*⁴⁺] calcd. for C₉₃H₈₃F₇N₁₄O₁₄S⁴⁺ 446.1450 found: 446.1452; [*M*⁴⁺-H⁺] calcd.


for C₉₃H₈₃F₇N₁₄O₁₄S³⁺ 594.8602 found: 594.8590.




P_{4-e}: ¹H NMR (600 MHz, Deuterium Oxide, 1%MeOH) δ 9.13 – 9.02 (m, 8H), 8.58 (dd, *J* = 25.6, 8.6 Hz, 7H), 8.40 (d, *J* = 43.6 Hz, 5H), 8.17 – 8.10 (m, 7H), 8.08 (d, *J* = 6.9 Hz, 1H), 7.97 – 7.83 (m, 8H), 7.11 – 6.67 (m, 9H), 6.16 – 6.08 (m, 6H), 6.05 (d, *J* = 16.0 Hz, 3H), 3.92 – 3.46 (m, 3H), 3.01 – 2.84 (m, 1H), 2.81 (dd, *J* = 13.8, 6.5 Hz, 1H), 2.75 – 2.65 (m, 1H), 2.65 – 2.59 (m, 1H), 2.54 – 2.43 (m, 2H), 2.35 – 1.45 (m, 4H), 1.38 – 1.13 (m, 2H), 1.12 – 0.77 (m, 1H). ¹³C NMR (151 MHz, Deuterium Oxide, 1%MeOH) δ 172.62, 168.41, 163.34, 147.06, 145.39, 137.21, 136.02, 133.88, 130.12, 129.61, 129.35, 128.32, 119.83, 117.89, 115.96, 114.03, 64.92, 60.39, 54.34, 53.77, 51.26, 47.77, 47.32, 37.02, 36.88, 30.42, 29.08, 24.28. ¹⁹F NMR (565 MHz, Deuterium Oxide, 1%MeOH) δ -124.65, -146.63 (dd, *J* = 174.6, 90.0 Hz). HRMS (ESI⁺-FTICR) *m/z* [*M*⁴⁺] calcd. for C₉₄H₇₇F₇N₁₂O₅S⁴⁺ 404.6432 found: 404.6435; [*M*⁴⁺-H⁺] calcd. for C₉₄H₇₆F₇N₁₂O₅S³⁺ 539.1885 found: 539.1891; [*M*⁴⁺-H⁺+TFA] calcd. for C₉₆H₇₇F₁₀N₁₂O₇S³⁺ 577.1861 found: 577.1876.




P₄-f: HRMS (ESI⁺-FTICR) m/z [M⁴⁺+H⁺] calcd. for C₉₂H₈₀F₇N₁₆O₇S⁵⁺ 337.1195 found: 337.1196; [M⁴⁺] calcd. for C₉₂H₇₉F₇N₁₆O₇S⁴⁺ 421.1476 found: 421.1476; [M⁴⁺-H⁺] calcd. for C₉₂H₇₉F₇N₁₆O₇S³⁺ 561.5303 found: 561.5302.




P₄-g: HRMS (ESI⁺-FTICR) m/z [M⁴⁺] calcd. for C₈₈H₇₆F₇N₁₃O₈S²⁺ 409.8812 found: 409.8809; [M⁴⁺-H⁺] calcd. for C₈₈H₇₅F₇N₁₃O₈S³⁺ 546.1725 found: 546.1724.




P₄-k: HRMS (ESI⁺-FTICR) m/z [M⁴⁺+H⁺] calcd. for C₁₁₈H₁₀₅F₇N₁₆O₁₉S⁵⁺ 449.3409 found: 449.3400; [M⁴⁺] calcd. for C₁₁₈H₁₀₄F₇N₁₆O₁₉S⁴⁺ 561.4243 found: 561.4232; [M⁴⁺-H⁺] calcd. for C₉₂H₇₉F₇N₁₆O₇S³⁺ 747.8940 found: 747.8937.



FITC-DEVD: HRMS (ESI⁺-FTICR) m/z [M+H]⁺ calcd. for C₄₅H₅₁N₆O₁₇S⁺ 979.3026 found: 979.3045.




P₄-a: ¹H NMR (600 MHz, Deuterium Oxide) δ 9.16 – 9.05 (m, 8H), 8.67 – 8.33 (m, 12H), 8.15 (q, *J* = 6.4, 5.5 Hz, 8H), 7.92 (d, *J* = 4.2 Hz, 8H), 6.19 – 6.07 (m, 8H), 3.46 (dd, *J* = 11.7, 6.5 Hz, 1H), 3.38 (q, *J* = 6.0 Hz, 1H), 3.06 – 2.91 (m, 3H), 2.60 (dd, *J* = 14.6, 7.9 Hz, 1H), 1.87 (d, *J* = 5.8 Hz, 2H), 1.61 – 1.41 (m, 2H). ¹³C NMR (151 MHz, Deuterium Oxide) δ 170.75, 146.46, 146.37, 144.72, 144.69, 136.02, 135.87, 129.05, 128.73, 128.67, 119.15, 115.29, 64.26, 52.01, 34.64, 30.61, 25.40. ¹⁹F NMR (565 MHz, Deuterium Oxide) δ -124.83 (d, *J* = 81.0 Hz, 1F), -146.00 – -147.60 (m, 6F). HRMS (ESI⁺-FTICR) *m/z* [M⁴⁺-H⁺] calcd. for C₇₈H₆₁F₇N₁₁O₆S³⁺ 470.8133 found: 470.8143.




P₄-2a: ¹H NMR (400 MHz, Deuterium Oxide) δ 9.07 (d, *J* = 6.0 Hz, 8H), 8.69 – 8.31 (m, 12H), 8.12 (t, *J* = 6.8 Hz, 8H), 7.91 (d, *J* = 6.0 Hz, 8H), 6.10 (d, *J* = 3.4 Hz, 8H), 3.46 – 3.26 (m, 4H), 3.06 – 2.81 (m, 6H), 2.72 – 2.44 (m, 2H), 1.89 (q, *J* = 7.7 Hz, 4H), 1.67 – 1.39 (m, 4H). ¹³C NMR (151 MHz, Deuterium Oxide) δ 173.46, 172.20, 170.80, 146.46, 146.38, 144.73, 144.69, 142.48, 138.03, 136.58, 136.18, 136.05, 135.73, 135.17, 129.45, 129.33, 129.12, 128.73, 128.69, 120.55, 118.64, 117.22, 115.28, 64.26, 52.88, 52.20, 52.06, 40.64, 34.73, 30.79, 25.46. ¹⁹F

NMR (565 MHz, Deuterium Oxide) δ -124.27(1F), -124.83 (1F), -146.66 (d, $J = 69.5$ Hz, 2F), -147.28 (2F). HRMS (ESI⁺-FTICR) m/z [M⁴⁺] calcd. for C₈₈H₇₈F₆N₁₄O₁₂S₂⁴⁺ 425.1312 found: 425.1315; [M⁴⁺-H⁺] calcd. for C₈₈H₇₇F₆N₁₄O₁₂S₂³⁺ 566.5058 found: 566.5063; [M⁴⁺-2H⁺+Na⁺] calcd. for C₈₈H₇₆F₆N₁₄NaO₁₂S₂³⁺ 573.8331 found: 573.8337; [M⁴⁺-2H⁺+K⁺] calcd. for C₈₈H₇₆F₆KN₁₄O₁₂S₂³⁺ 579.1578 found: 579.1567.




P₅-a

P₅-a: HRMS (ESI⁺-FTICR) m/z [M⁴⁺] calcd. for C₇₀H₇₈F₇N₁₁O₆S⁴⁺ 333.3931 found: 333.3928; [M⁴⁺-H⁺] calcd. for C₇₀H₇₇F₇N₁₁O₆S³⁺ 444.1884 found: 444.1886.




P₆-a


P₆-a: HRMS (ESI⁺-FTICR) m/z [M⁴⁺] calcd. for C₇₄H₈₆F₇N₁₁O₁₀S⁴⁺ 363.4037 found: 363.4034; [M⁴⁺-H⁺] calcd. for C₇₄H₈₅F₇N₁₁O₁₀S³⁺ 444.1884 found: 444.1886.




P7-a: HRMS (ESI⁺-FTICR) m/z [M⁴⁺] calcd. for C₈₂H₁₀₂F₇N₁₁O₁₄S⁴⁺ 407.4299 found: 407.4298; [M⁴⁺-H⁺] calcd. for C₈₂H₁₀₁F₇N₁₁O₁₄S³⁺ 542.9041 found: 542.9049.




P8-a: HRMS (ESI⁺-FTICR) m/z [M⁴⁺] calcd. for C₇₈H₇₈F₇N₁₁O₆S⁴⁺ 357.3931 found: 357.3924; [M⁴⁺-H⁺] calcd. for C₇₈H₇₇F₇N₁₁O₆S³⁺ 476.1884 found: 476.1892.




P₉-a: HRMS (ESI⁺-FTICR) m/z [M⁴⁺] calcd. for C₇₄H₈₂F₇N₂₃O₆S⁴⁺ 388.4101 found: 388.4103; [M⁴⁺-H⁺] calcd. for C₇₄H₈₁F₇N₂₃O₆S³⁺ 517.5444 found: 517.5447.




P₁₀-a: HRMS (ESI⁺-FTICR) m/z [M⁴⁺] calcd. for C₇₀H₇₈F₇N₇O₆P₄S⁴⁺ 350.3638 found: 350.3628; [M⁴⁺-H⁺] calcd. for C₇₀H₇₇F₇N₇O₆P₄S³⁺ 466.8160 found: 466.8161.



P_{11-a}: HRMS (ESI⁺-FTICR) m/z [M⁴⁺] calcd. for C₆₆H₆₆F₇N₇O₆S₅⁴⁺ 336.3386 found: 336.3384; [M⁴⁺-H⁺] calcd. for C₆₆H₆₅F₇N₇O₆S₅³⁺ 427.4427 found: 427.4432.



P_{12-a}: HRMS (ESI⁺-FTICR) m/z [M+H²⁺] calcd. for C₈₂H₉₆F₇N₇O₂₂S₄⁴⁺ 847.8103 found: 847.8080.



P₁₃-a

P₁₃-a: HRMS (ESI-FTICR) m/z [M^4] calcd. for $C_{54}H_{26}F_{15}N_7O_{18}S_5^{4-}$ 376.32430 found: 376.3384; [M^4+H^+] calcd. for $C_{54}H_{26}F_{15}N_7O_{18}S_5^{3-}$ 501.9931 found: 501.9928; [M^4+Na^+] calcd. for $C_{54}H_{26}F_{15}N_7NaO_{18}S_5^{3-}$ 509.3204 found: 509.3202.

II. Supporting Tables and Figures

Solvent A – water (0.05% v/v TFA), Solvent B – MeOH. Detection wavelength – 395 nm.

Time/min	Rate of flow mL/min	A%	B%
0	1	80	20
2	1	48	52
17	1	30	70
17.1	1	5	95
18.9	1	5	95
19	1	80	20
20	1	80	20

Table S1. Method A was adopted during optimizing reaction conditions.

Solvent A – water (0.05% v/v TFA), Solvent B – MeOH. Detection wavelength – 395 nm.

Time/min	Rate of flow mL/min	A%	B%
0	1	80	20
5	1	55	45
22	1	25	75
22.1	1	5	95
23.9	1	5	95
24	1	80	20
25	1	80	20

Table S2. Method B.

Solvent A – water (0.05% v/v TFA), Solvent B – MeOH. Detection wavelength – 395 nm.

Time/min	Rate of flow mL/min	A%	B%
0	5	80	20
5	5	55	45
22	5	25	75
22.1	5	5	95
23.9	5	5	95
24	5	80	20
25	5	80	20

Table S3. Method C.

Solvent A – water (0.05% v/v TFA), Solvent B – acetonitrile. Detection wavelength – 395 nm.

Time/min	Rate of flow mL/min	A%	B%
0	1	90	10
40	1	40	60
41	1	0	100
55	1	0	100

Table S4. Method D.

		P₁	P₂	P₃
ΔE_{ST} /eV	S ₁ -T ₁ , S ₁ -T ₂	1.24	0.658	0.714
	S ₁ -T ₃	-0.0197	0.0432	0.0405
SOC constants /cm ⁻¹	S ₁ -T ₁ , S ₁ -T ₂	0.0418	0.604	1.26
	S ₁ -T ₃	--	1.70	1.85
k_{ISC} /s ⁻¹	S ₁ -T ₁ , S ₁ -T ₂	2.48×10 ⁵	2.63×10 ⁷	6.35×10 ⁷
	S ₁ -T ₃	--	6.98×10 ⁵	5.58×10 ⁵

Table S5. Computational calculation data of **P₁₋₃**.




Figure S1. Correlations between integration area and content of P₄, P₄-a, and P₄-2a at 395 nm.

HPLC spectra of reaction optimization between P₄ and a.




Figure S2. HPLC analysis of reaction mixture in Entry 1.




Figure S3. HPLC analysis of reaction mixture in Entry 2.




Figure S4. HPLC analysis of reaction mixture in Entry 3.




Figure S5. HPLC analysis of reaction mixture in Entry 4.




Figure S6. HPLC analysis of reaction mixture in Entry 5.




Figure S7. HPLC analysis of reaction mixture in Entry 6.




Figure S8. HPLC analysis of reaction mixture in Entry 7.




Figure S9. HPLC analysis of reaction mixture in Entry 8.




Figure S10. HPLC analysis of reaction mixture in Entry 9.




Figure S11. HPLC analysis of reaction mixture in Entry 10.




Figure S12. a) Percentage of P_4 (1 mM) and its bioconjugate when reacting with GSH (a, 1 mM) at different time points. b) Experimental determination of the reaction rate constant.




Figure S13. a) Stability of **P_{4-a}** at GSH abundant conditions determined by HPLC analysis. A: PBS (pH 7.4), 37 °C, 24 h. B: GSH (2 mM), PBS (pH 7.4), 37 °C, 24 h. C: GSH (5 mM), PBS (pH 7.4), 37 °C, 24 h. D: GSH (10 mM), PBS (pH 7.4), 37 °C, 24 h. E: GSH (10 mM), PBS (pH 6.8), 37 °C, 24 h. b) Content of **P₄** (red) and **P_{4-a}** (blue) in GSH (10 mM), PBS (pH 7.4) at 37 °C at different time points determined by HPLC analysis.




Figure S14. HPLC analysis of cell lysates of HeLa cells treated with **P₄-a** (10 μ M) for different time period (0, 1, 2, 5, 7, 11, 24 h).




Figure S15. Determination of cell stability of **P₄-a** by SDS-PAGE. Coomassie brilliant blue (CBB)-stained gel showed protein weights of cell lysates in which HeLa cells were incubated with **P₄-a** for different time period (0, 1, 2, 5, 7, 11, 24 h). In gel fluorescence scanning showed no porphyrinic emission (red).




Figure S16. Δ OD of DPBF absorbance change at 415 nm for **P₄**, **P₄-a**, and **P₄-2a** in toluene (0.1% v/v DMSO) at room temperature.




Figure S17. Dark cytotoxicity evaluation (mean \pm SD, three biological repeats) of P₄, P₄-a, and P₄-2a in HeLa cells.




Figure S18. Photocytotoxicity evaluation (mean \pm SD, three biological repeats) of P₄, P₄-a, and P₄-2a in HeLa cells.





Figure S19. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₄** and **b**.




Figure S20. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₄** and **c**.




Figure S21. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₄** and **d**.




Figure S22. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₄** and **e**.




Figure S23. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₄** and **f**.




Figure S24. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₄** and **g**.




Figure S25. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₄** and **a**.




Figure S26. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₅** and **a**.




Figure S27. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₆** and **a**.




Figure S28. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₇** and **a**.




Figure S29. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₈** and **a**.




Figure S30. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₉** and **a**.





Figure S31. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₁₀** and **a**.



Figur S32. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₁₁** and **a**.




Figure S33. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₁₂** and **a**.




Figure S34. UV-Vis spectrum of of reaction mixture between P_{13} and **a**.





Figure S35. HRMS (ESI-FTICR) spectrum of **P₁₃-a**.

Using sulfo-DBCO- NH₂ (**h**):



P₉-ah: HRMS (ESI⁺-FTICR) m/z [M⁴⁺] calcd. for C₁₅H₁₆F₇N₃O₂S₅⁴⁺ 815.7823 found: 815.7809.





Figure S36. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₉-a** and **h**.

Using DBCO-PEG4-NHS (**i**):



P₉-ai: HRMS (ESI⁺-FTICR) m/z [M⁴⁺] calcd. for C₂₁₀H₂₄₀F₇N₃S₅O₄₆S⁴⁺ 1038.1776 found: 1038.1747.





Figure S37. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₉-a** and **i**.

Using Disulfo-Cy5-DBCO (**j**):



P₉-aj: HRMS (ESI⁺-FTICR) m/z $[\text{M}-\text{H}]^{3+}$ calcd. for $\text{C}_{274}\text{H}_{292}\text{F}_7\text{N}_3\text{O}_3\text{S}_9$ 1718.9825 found: 1718.9794.




Figure S38. HPLC-UV chromatogram at 395 nm of reaction mixture between **P₉-a** and **j**.




Figure S39. MALDI-TOF spectra of EGFP (magenta) and IAA-EGFP (green).




Figure S40. SDS-PAGE gel of β -fluorine-cysteine S_NAr reaction mixtures between BSA and P_4/P_{13} . Coomassie brilliant blue (CBB)-stained gel showed increased protein weights after β -fluorine-cysteine S_NAr reaction. In gel fluorescence scanning showed porphyrinic emission (red).




Figure S41. MALDI-TOF spectrum of free Sav (magenta) and P₁₃-Sav (green).




Figure S42. Body weight curves of tumor mice in each treatment group (n = 3, mean ± SD).




Figure S43. Hematoxylin and eosin (H&E)-stained slice images of major organs from different groups. All images share the same scale bar: 100 μ m.




Figure S44. ^1H NMR spectrum (400 MHz, Chloroform-*d*) of 2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin.





Figure S45. ^{13}C NMR spectrum (400 MHz, Chloroform-*d*) of 2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin.



Meas. m/z	#	Ion Formula	Score	m/z	err [ppm]	Mean err [ppm]	mSigma	rdb	e ⁻ Conf	N-Rule
1126.880516	1	C ₄₈ H ₂₇ Br ₄ F ₈ N ₄	100.00	1126.883599	2.7	-0.5	118.0	40.0	even	ok

Figure S46. HRMS (MALDI-FTICR) spectrum of 2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin.




Figure S47. Normalized FT-IR spectrum of 2,3,7,8,12,13,17,18-octafluoro-5,10,15,20-tetrakis[4-bromomethylphenyl]porphyrin.




Figure S48. ¹H NMR spectrum (500 MHz, Methanol-*d*₄) of P₄.




Figure S49. ¹³C NMR spectrum (126 MHz, Methanol-*d*₄) of P₄.




Figure S50. ^{19}F NMR spectrum (471 MHz, Methanol- d_4) of **P4**.




Figure S51. HSQC NMR spectrum (500 MHz) of **P4**.






Figure S52. HRMS (ESI⁺-FTICR) spectrum of P4.




Figure S53. Normalized FT-IR spectrum of P₄.




Figure S54. ^1H NMR spectrum (400 MHz, Methanol- d_4) of P_5 .





Figure S55. ^{19}F NMR spectrum (471 MHz, Methanol- d_4) of P_5 .



Meas. m/z	#	Ion Formula	Score	m/z	err [ppm]	Mean err [ppm]	mSigma	rdb	e ⁻	Conf	N-Rule
261.623432	1	C60H62F8N8	100.00	261.622816	-2.4	-2.9	34.6	10.0	even		ok

Figure S56. HRMS spectrum (ESI⁺-FTICR) spectrum of **P₅**.




Figure S57. Normalized FT-IR spectrum of P₅.

8.35
8.33
8.07
8.05

5.03
4.94

4.27

3.75
3.38
3.32




Figure S58. ¹H NMR spectrum (400 MHz, Methanol-*d*₄) of P₆.




Figure S59. ^{19}F NMR spectrum (471 MHz, Methanol- d_4) of **P6**.





Figure S60. HRMS (ESI⁺-FTICR) spectrum of **P₆**.




Figure S61. Normalized FT-IR spectrum of **P6**.




Figure S62. ^1H NMR spectrum (400 MHz, Methanol- d_4) of **P7**.







Figure S63. ^{19}F NMR spectrum (471 MHz, Methanol- d_4) of **P7**.



Meas. m/z	#	Ion Formula	Score	m/z	err [ppm]	Mean err [ppm]	mSigma	rdb	e ⁻ Conf	N-Rule
335.660366	1	C72H86F8N8O8	100.00	335.660473	0.3	0.0	52.5	32.0	even	ok
447.211531	1	C72H85F8N8O8	100.00	447.211539	0.0	-0.8	16.8	32.0	even	ok
485.209271	1	C74H86F11N8O10	100.00	485.209160	-0.2	-0.7	23.5	32.0	even	ok






Figure S64. HRMS (ESI+-FTICR) spectrum of **P₇**.




Figure S65. Normalized FT-IR spectrum of **P₇**.




Figure S66. ¹H NMR spectrum (400 MHz, Methanol-*d*₄) of **P8**.




Figure S67. ¹⁹F NMR spectrum (471 MHz, Methanol-*d*₄) of **P8**.





Figure S68. HRMS (ESI⁺-FTICR) spectrum of P₈.




Figure S69. Normalized FT-IR spectrum of **P₈**.




Figure S70. ¹H NMR spectrum (400 MHz, Chloroform-*d*) of 2-azido-N,N-dimethylethan-1-amine.





Figure S71. HRMS (ESI⁺-FTICR) spectrum of 2-azido-N,N-dimethylethan-1-amine.




Figure S72. ¹H NMR spectrum (400 MHz, Methanol-*d*₄) of **P**₉.




Figure S73. ¹⁹F NMR spectrum (471 MHz, Methanol-*d*₄) of **P**₉.






Figure S74. HRMS spectrum (ESI⁺-FTICR) of P₉.




Figure S75. Normalized FT-IR spectrum of **P9**.




Figure S76. ¹H NMR spectrum (400 MHz, Methanol-*d*₄) of **P**₁₀.




Figure S77. ¹⁹F NMR spectrum (565 MHz, Methanol-*d*₄) of **P**₁₀.






Figure S78. HRMS spectrum (ESI⁺-FTICR) of P₁₀.




Figure S79. Normalized FT-IR spectrum of **P₁₀**.




Figure S80. ^1H NMR spectrum (400 MHz, Methanol- d_4) of P_{11} .




Figure S81. ^{19}F NMR spectrum (471 MHz, Methanol- d_4) of P_{11} .




Figure S82. HRMS (ESI⁺-FTICR) spectrum of **P₁₁**.




Figure S83. Normalized FT-IR spectrum of **P11**.





Figure S84. ¹H NMR spectrum (400 MHz, Chloroform-*d*) of 3-(2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy)-benzaldehyde.



Meas. m/z	#	Ion Formula	Score	m/z	err [ppm]	Mean err [ppm]	mSigma	rdb	e ⁻	Conf	N-Rule
291.119595	1	C ₁₄ H ₂₀ NaO ₅	100.00	291.120294	2.4	1.7	31.4	5.0	even		ok

Figure S85. HRMS (ESI⁺-FTICR) spectrum of 3-(2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy)-benzaldehyde.




Figure S86. ^1H NMR spectrum (400 MHz, Chloroform-*d*) of **P**₁₂.




Figure S87. ^{19}F NMR spectrum (471 MHz, Chloroform-*d*) of **P**₁₂.






Figure S88. HRMS (ESI⁺-FTICR) spectrum of P₁₂.




Figure S89. Normalized FT-IR spectrum of **P12**.




Figure S90. ^1H NMR spectrum (400 MHz, Chloroform- d) of 2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(2,6-difluorophenyl)porphyrin.




Figure S91. ^{19}F NMR spectrum (400 MHz, Methanol- d_4) of 2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(2,6-difluorophenyl)porphyrin.





Figure S92. HRMS spectrum (ESI⁺-FTICR) spectrum of 2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(2,6-difluorophenyl)porphyrin.




Figure S93. Normalized FT-IR spectrum of 2,3,7,8,12,13,17,18-Octafluoro-5,10,15,20-tetrakis(2,6-difluorophenyl)porphyrin.




Figure S94. ¹H NMR spectrum (400 MHz, Methanol-*d*₄) of P₁₃.




Figure S95. ¹⁹F NMR spectrum (471 MHz, Methanol-*d*₄) of P₁₃.





Figure S96. HRMS (ESI-FTICR) spectrum of P₁₃.




Figure S97. Normalized FT-IR spectrum of **P₁₃**.




Figure S98. ^1H NMR spectrum (600 MHz, Deuterium Oxide) of **P₄-a**.




Figure S99. ^{13}C NMR spectrum (151 MHz, Deuterium Oxide) of **P₄-a**.




Figure S100. ^{19}F NMR spectrum (565 MHz, Deuterium Oxide) of **P₄-a**.




Figure S101. HSQC spectrum (600 MHz, Deuterium Oxide) of **P₄-a**.




Figure S102. HRMS (ESI⁺-FTICR) spectrum of P₄-a.




Figure S103. Normalized FT-IR spectrum of **P₄-a**.




Figure S104. ^1H NMR spectrum (400 MHz, Deuterium Oxide) of **P₄-2a**.




Figure S105. ^{13}C NMR spectrum (151 MHz, Deuterium Oxide) of **P₄-2a**.




Figure S106. ^{19}F NMR spectrum (565 MHz, Deuterium Oxide) of **P₄-2a**.







Figure S107. HSQC spectrum (600 MHz, Deuterium Oxide) of **P₄-2a**.



Meas. m/z	#	Ion Formula	Score	m/z	err [ppm]	Mean err [ppm]	mSigma	rdb	e ⁻ Conf	N-Rule
425.131468	1	C88H78F6N14O12S2	100.00	425.131183	-0.7	-0.4	40.7	60.0	even	ok
566.506317	1	C88H77F6N14O12S2	100.00	566.505818	-0.9	-0.6	59.4	60.0	even	ok
573.833675	1	C88H76F6N14NaO12S2	100.00	573.833133	-0.9	-2.1	44.1	60.0	even	ok
579.156674	1	C88H76F6KN14O12S2	100.00	579.157779	1.9	1.8	87.1	60.0	even	ok






Figure S108. HRMS (ESI⁺-FTICR) spectrum of **P₄-2a**.







Figure S109. Normalized FT-IR spectrum of **P₄-2a**.






Figure S110. HRMS (ESI⁺-FTICR) spectrum of **P4-b**.




Figure S111. HRMS (ESI⁺-FTICR) spectrum of IAA-b.




Figure S112. ^1H NMR spectrum (600 MHz, Deuterium Oxide) of **P₄-c**.




Figure S113. ^{13}C NMR spectrum (151 MHz, Deuterium Oxide, 1% MeOH) of **P₄-c**.




Figure S114. ^{19}F NMR spectrum (565 MHz, Deuterium Oxide, 1% MeOH) of **P4-c**.





Figure S115. HSQC spectrum (600 MHz, Deuterium Oxide, 1% MeOH) of



Meas. m/z	#	Ion Formula	Score	m/z	err [ppm]	Mean err [ppm]	mSigma	rdb	e ⁻ Conf	N-Rule
375.627016	1	C85H69F7N12O5S	100.00	375.627522	1.3	1.0	47.4	58.0	even	ok
500.501244	1	C85H68F7N12O5S	100.00	500.500937	-0.6	-0.4	45.7	58.0	even	ok
538.499746	1	C87H69F10N12O7S	100.00	538.498558	-2.2	-2.8	66.7	58.0	even	ok

P4-c.





Figure S116. HRMS (ESI⁺-FTICR) spectrum of **P4-c**.






Figure S117. HRMS (ESI⁺-FTICR) spectrum of P₄-d.




Figure S118. ^1H NMR spectrum (600 MHz, Deuterium Oxide, 1% MeOH) of **P₄-e**.




Figure S119. ^{13}C NMR spectrum (151 MHz, Deuterium Oxide, 1% MeOH) of **P₄-e**.




Figure S120. ^{19}F NMR spectrum (565 MHz, Deuterium Oxide, 1% MeOH) of **P₄-e**.







Figure S121. HSQC spectrum (600 MHz, Deuterium Oxide, 1% MeOH) of **P₄-e**.









Figure S122. HRMS (ESI⁺-FTICR) spectrum of **P₄-e**.






Figure S123. HRMS (ESI⁺-FTICR) spectrum of **P₄-f**.






Figure S124. HRMS (ESI⁺-FTICR) spectrum of P₄-g.






Figure S125. HRMS (ESI⁺-FTICR) spectrum of P₄-k.





Figure S126. HRMS (ESI⁺-FTICR) spectrum of P₅-a.






Figure S127. HRMS (ESI⁺-FTICR) spectrum of P₆-a.






Figure S128. HRMS (ESI⁺-FTICR) spectrum of P7-a.









Figure S129. HRMS (ESI⁺-FTICR) spectrum of P₈-a.



Meas. m/z	#	Ion Formula	Score	m/z	err [ppm]	Mean err [ppm]	mSigma	rdb	e ⁻ Conf	N-Rule
388.410290	1	C74H82F7N23O6S	100.00	388.410135	-0.4	-1.4	41.4	46.0	even	ok
517.544675	1	C74H81F7N23O6S	100.00	517.544422	-0.5	-1.4	41.1	46.0	even	ok



Meas. m/z	#	Ion Formula	Score	m/z	err [ppm]	Mean err [ppm]	mSigma	rdb	e ⁻ Conf	N-Rule
388.410290	1	C74H82F7N23O6S	100.00	388.410135	-0.4	-1.4	41.4	46.0	even	ok
517.544675	1	C74H81F7N23O6S	100.00	517.544422	-0.5	-1.4	41.1	46.0	even	ok



Meas. m/z	#	Ion Formula	Score	m/z	err [ppm]	Mean err [ppm]	mSigma	rdb	e ⁻ Conf	N-Rule
388.410290	1	C74H82F7N23O6S	100.00	388.410135	-0.4	-1.4	41.4	46.0	even	ok
517.544675	1	C74H81F7N23O6S	100.00	517.544422	-0.5	-1.4	41.1	46.0	even	ok

Figure S130. HRMS (ESI⁺-FTICR) spectrum of P₉-a.









Figure S131. HRMS (ESI⁺-FTICR) spectrum of P₁₀-a.






Figure S132. HRMS (ESI⁺-FTICR) spectrum of P₁₁-a.




Figure S133. HRMS (ESI⁺-FTICR) spectrum of P₁₂-a.




Figure S134. HRMS (ESI⁺-FTICR) spectrum of **FITC-DEVD**.




Figure S135. Raw image for **Figure S15-CBB**.




Figure S136. Raw image for **Figure S15-in gel**.




Figure S137. Raw image for **Figure 4c-CBB**.




Figure S138. Raw image for **Figure 4c-in gel**.




Figure S139. Raw image for **Figure 5b**.




Figure S140. Raw image for **Figure 7g- β -actin.**



Figure S141. Raw image for **Figure 7g-caspase 3.**




Figure S142. Raw image for **Figure S40-CBB.**



Figure S143. Raw image for **Figure S40**-in gel.

III. Reference

- 1 Hu, J.-Y. *et al.* Highly near-IR emissive ytterbium(III) complexes with unprecedented quantum yields. *Chem. Sci.* **8**, 2702-2709 (2017).
- 2 Hou, Y., Yuan, J., Zhou, Y., Yu, J. & Lu, H. A Concise Approach to Site-Specific Topological Protein–Poly(amino acid) Conjugates Enabled by in Situ-Generated Functionalities. *J. Am. Chem. Soc.* **138**, 10995-11000 (2016).
- 3 Lu, J., Wang, H., Tian, Z., Hou, Y. & Lu, H. Cryopolymerization of 1,2-Dithiolanes for the Facile and Reversible Grafting-from Synthesis of Protein–Polydisulfide Conjugates. *J. Am. Chem. Soc.* **142**, 1217-1221 (2020).
- 4 M. J. Frisch *et al.* *Gaussian 09 (Revision E.01)*. (Gaussian Inc., 2009).
- 5 Francl, M. M. *et al.* Self - consistent molecular orbital methods. XXIII. A polarization - type basis set for second - row elements. *J. Chem. Phys.* **77**, 3654-3665 (1982).
- 6 Hariharan, P. C. & Pople, J. A. The influence of polarization functions on molecular orbital hydrogenation energies. *Theor. Chem. Acc.* **28**, 213-222 (1973).
- 7 Marenich, A. V., Cramer, C. J. & Truhlar, D. G. Universal solvation model based on solute electron density and a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions. *J. Phys. Chem. B* **113**, 6378-6396 (2009).
- 8 Chiodo, S. G. & Leopoldini, M. MolSOC: A spin–orbit coupling code. *Computer Physics Communications* **185**, 676-683 (2014).
- 9 Gao, X. *et al.* Evaluation of spin-orbit couplings with linear-response time-dependent density functional methods. *J. Chem. Theory Comput.* **13**, 515–524 (2017).
- 10 Niu, Y. L., Peng, Q. A., Deng, C. M., Gao, X. & Shuai, Z. G. Theory of excited state decays and optical spectra: application to polyatomic molecules. *Journal of Physical Chemistry A* **114**, 7817-7831 (2010).
- 11 Peng, Q., Niu, Y., Shi, Q., Gao, X. & Shuai, Z. Correlation function formalism for triplet excited state decay: combined spin-orbit and nonadiabatic couplings. *J. Chem. Theory Comput.* **9**, 1132-1143 (2013).
- 12 Shuai, Z. G., Peng, Q., Niu, Y. L. & Geng, H. *MOMAP, a molecular materials property prediction package, revision 0.2.004*. (Tsinghua University: Beijing, China, 2014).
- 13 Peng, Q. *et al.* Theoretical study of conversion and decay processes of excited triplet and singlet states in a thermally activated delayed fluorescence molecule. *J. Phys. Chem. C* **121**, 13448-13456 (2017).
- 14 Niu, Y., Li, W., Qian, P., Hua, G. & Shuai, Z. Molecular materials property prediction package (MOMAP) 1.0: a software package for predicting the luminescent properties and mobility of organic functional materials. *Molecular Physics* **116**, 1-13 (2018).